Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 12, 2018


(Exact name of registrant as specified in its charter)
Delaware 001-36728 56-2590442

(State or other jurisdiction

of incorporation)


File Number)

(IRS Employer

Identification No.)

465 State Route 17, Ramsey, New Jersey 07446
(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (201) 478-5552


(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company ý


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨



Item 8.01Other Events.


On June 12, 2018, ADMA Biologics, Inc., a Delaware corporation (the "Company"), announced that it has completed its previously announced sale of an aggregate of 8,368,200 shares of common stock, par value $0.0001 per share (the “Common Stock”), pursuant to the Company's existing shelf registration statement on Form S-3 (File No. 333-225048) (the “Offering”). The Company received gross proceeds of approximately $40.0 million, based on a public offering price of $4.78 per share, before deducting the underwriting discounts and commissions and estimated fees and expenses payable by the Company in connection with the Offering. The underwriters continue to have an option to purchase up to an additional 1,255,230 shares of Common Stock at the public offering price, before deducting underwriting discounts and commissions, which option expires July 8, 2018. Raymond James & Associates, Inc. acted as the sole book-running manager for the Offering. Oppenheimer & Co. Inc. acted as lead manager and Chardan Capital Markets, LLC acted as co-manager for the Offering.


A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.Description


5.1Opinion of DLA Piper LLP (US).


23.1Consent of DLA Piper LLP (US) (included in Exhibit 5.1).


99.1Press Release of the Company dated June 12, 2018.





Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


June 12, 2018 ADMA Biologics, Inc.
  By: /s/ Brian Lenz
    Name:  Brian Lenz
    Title: Vice President and Chief Financial Officer